Oncology & Cancer

Researchers report double dose of promising lung cancer findings

(Medical Xpress)—Researchers with UCLA's Jonsson Comprehensive Cancer Centerreport that two new experimental drugs have shown great promise in the treatment of patients with non–small-cell lung cancer, which accounts ...

Oncology & Cancer

Researchers develop new generation tumor-specific pro-IL-12

Interleukin-12 (IL-12), a potent inducer of cell-mediated immunity, can stimulate the anti-tumor effector functions of the activated T and NK cells for solid tumors rejection. However, clinical administration of IL-12 has ...

Oncology & Cancer

Prostaglandin E1 inhibits leukemia stem cells

Two drugs, already approved for safe use in people, may be able to improve therapy for chronic myeloid leukemia (CML), a blood cancer that affects myeloid cells, according to results from a University of Iowa study in mice.

Diseases, Conditions, Syndromes

Treatments explored for moderate-to-severe alopecia areata

(HealthDay)—For patients with alopecia areata (AA), treatment with an inhibitor of janus kinase (JAK)3 and the tyrosine kinase expressed in the hepatocellular carcinoma kinase family, ritlecitinib, and an inhibitor of tyrosine ...

Oncology & Cancer

Melanoma: dabrafenib and trametinib have added benefit

The German Institute for Quality and Efficiency in Health Care (IQWiG) investigated whether the drug combinations of dabrafenib plus trametinib and of encorafenib plus binimetinib have an added benefit in comparison with ...

Neuroscience

Findings reveal new mechanism of activation for ALK

ALK is a receptor tyrosine kinase that regulates important functions in the central nervous system. Scientists at St. Jude Children's Research Hospital have used leading-edge structural biology techniques to reveal in more ...

page 14 from 30